1-3 of 3
Anna Byrd
Close
Sort by
Journal Articles

Phase II Study of the Combination of Clofarabine Plus Idarubicin and Cytarabine (CIA) In Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML).

Kiran Naqvi, MD, Farhad Ravandi, MD, Hagop Kantarjian, MD, Gautam Borthakur, MD, Alessandra Ferrajoli, MD, Deborah A Thomas, MD, Charles Asa Koller, Marina Konopleva, MD, PhD, Anna Byrd, RN, Monica Kwari, BSN, Stefan Faderl, MD
Journal: Blood
Blood (2010) 116 (21): 1061.
https://doi.org/10.1182/blood.V116.21.1061.1061
Published: 2010
Journal Articles

Oral (po) and Intravenous (iv) Clofarabine for Patients (pts) with Myelodysplastic Syndrome (MDS)

Stefan Faderl, Guillermo Garcia-Manero, Farhad Ravandi, Gautam Borthakur, Zeev Estrov, Deborah A. Thomas, Varsha Gandhi, William Plunkett, Anna Byrd, Monica Kwari, Hagop M. Kantarjian
Journal: Blood
Blood (2008) 112 (11): 222.
https://doi.org/10.1182/blood.V112.11.222.222
Published: 2008
Journal Articles

Results of an Exploratory Study of Oral (po) and Intravenous (iv) Clofarabine in Patients with Myelodysplastic Syndrome.

Stefan Faderl, MD, Guillermo Garcia-Manero, MD, Varsha Gandhi, PhD, MS, BS, Farhad Ravandi, MD, Gautam Borthakur, MD, Deborah A. Thomas, MD, Alessandra Ferrajoli, MD, Zeev Estrov, MD, William Plunkett, PhD, BS, Anna Byrd, RN, Monica Kwari, RN, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2007) 110 (11): 1455.
https://doi.org/10.1182/blood.V110.11.1455.1455
Published: 2007